PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS OF POLYPEPTIDE DELIVERY

被引:31
作者
MAZER, NA
机构
[1] TheraTech, Inc. and Department of Pharmaceutics, University of Utah, Salt Lake City
关键词
input function; modelling; pharmacodynamics; pharmacokinetics; polypeptides;
D O I
10.1016/0168-3659(90)90146-K
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The rational design and development of drug delivery systems for polypeptide compounds requires a quantitative understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of the compound in the intended therapeutic indication. In particular it is necessary to define the characteristics of the input function, i.e. the rate and time course of systemic drug input, that will maximize the therapeutic effect, minimize unwanted side effects and prevent tachyphylaxis from occurring. This paper reviews the general concepts of input function, PK and PD, and illustrates these concepts using two examples from the literature: (1) Sandoz compound SMS 201-995 and (2) gonadotropin-releasing hormone (GnRH). For SMS 201-995, a continuous (zero-order) input function is shown to be optimal for suppressing growth hormone secretion in the treatment of acromegaly. For GnRH, a pulsatile input function is optimal for stimulating pituitary gonadotropin secretion, whereas continuous input leads to a paradoxical suppression of gonadotropin secretion. These examples further illustrate the types of novel experimental approaches, using programmable infusion pumps, that are needed for investigating the relationship between PK and PD, and for defining the optimal input function experimentally. In addition, we show how mathematical models may be used to describe the interrelationships between input function, PK and PD. For SMS 201-995, a model based on the "effect compartment" concept offers a self-consistent description of the linkage between PK and PD and provides insight into the superiority of continuous input in the treatment of acromegaly. For GnRH, the complex relationship between input function and gonadotropin secretion is modelled on the basis of heuristic concepts that relate the time-averaged occupancy of the GnRH-receptors (by GnRH) to the expression of GnRH-receptors by the pituitary (i.e. down and up regulation). Together these examples illustrate the diversity of input functions that will be needed in polypeptide delivery and the novel experimental and theoretical approaches required for defining them. © 1990.
引用
收藏
页码:343 / 356
页数:14
相关论文
共 50 条
  • [31] PET for in vivo pharmacokinetic and pharmacodynamic measurements
    Gupta, N
    Price, PM
    Aboagye, EO
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (16) : 2094 - 2107
  • [32] Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy
    Balthasar, JP
    Fung, HL
    LIFE SCIENCES, 1996, 58 (07) : 535 - 543
  • [33] Pharmacokinetic-pharmacodynamic modeling:: Why?
    Pérez-Urizar, J
    Granados-Soto, V
    Flores-Murrieta, FJ
    Castañeda-Hernández, G
    ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (06) : 539 - 545
  • [34] SUBLINGUAL CAPTOPRIL - A PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION
    ALFURAIH, TA
    MCELNAY, JC
    ELBORN, JS
    RUSK, R
    SCOTT, MG
    MCMAHON, J
    NICHOLLS, DP
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (04) : 393 - 398
  • [35] An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease
    Danhof, M
    Van der Geest, R
    Van Laar, T
    Boddé, HE
    ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (03) : 253 - 263
  • [36] Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs
    Dasa, Siva Sai Krishna
    Suzuki, Ryo
    Mugler, Emily
    Chen, Lanlin
    Jansson-Lofmark, Rasmus
    Michaelsson, Erik
    Lindfors, Lennart
    Klibanov, Alexander L.
    French, Brent A.
    Kelly, Kimberly A.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (08) : 2565 - 2574
  • [37] Intrapericardial therapeutics: A pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery
    Ujhelyi, MR
    Hadsall, KZ
    Euler, DE
    Mehra, R
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2002, 13 (06) : 605 - 611
  • [38] Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development
    Dingemanse, Jasper
    Krause, Andreas
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S53 - S58
  • [39] The use of transgenic mice in pharmacokinetic and pharmacodynamic studies
    Elmquist, WF
    Miller, DW
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (04) : 422 - 435
  • [40] Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol
    Krumpl, Guenther
    Ulc, Ivan
    Trebs, Michaela
    Hodisch, Juri
    Kadlecova, Pavla
    Husch, Bernhard
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)